References
- Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-9.
- Oosterhuis HJ. The natural course of myasthenia gravis: A long term follow up study. J Neurol Neurosurg Psychiatry 1989;52:1121-7.
- Angelini C, Martignago S, Biscigli M, Albertini E. Myasthenia gravis with anti-MuSK antibodies: Clinical features and histopathological changes. In: A Look into Myasthenia Gravis. London: IntechOpen Limited; 2012.
- Levy A. Pituitary disease: Presentation, diagnosis, and management. J Neurol Neurosurg Psychiatry 2004;75:iii47-52.
- Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011;7:257-66.
- Kasem MA, Kassem M, Taha AN, Kamal AS. Ocular motility disorders: Unusual presentation of pituitary adenoma. J Egypt Ophthalmol Soc 2018;111:43-8.
- Vance M. Pituitary adenoma: A clinician’s perspective. Endocr Pract 2008;14:757-63.
- Natarajan D, Tatineni S, Ponnapalli SP, Sachdeva V. Pituitary adenoma presenting as acute onset isolated complete third cranial nerve palsy without vision changes. BMJ Case Rep 2020;13:e232490.
- Gaballa S, Lindsay J, AlJaf A, Hlaing KM, Patel K. Acute unilateral oculomotor nerve palsy as the initial presenting sign of nonfunctioning apoplectic gonadotroph adenoma. Cureus 2020;12:e8819.
- Farfouti MT, Ghabally M, Roumieh G, Farou S, Shakkour M. A rare association between myasthenia gravis and a growth hormone secreting pituitary macroadenoma: A single case report. Oxf Med Case Rep 2019;2019:omz064.
- Hokkanen E. Myasthenia gravis. A clinical analysis of the total material from Finland with special reference to endocrinological and neurological disorders. Ann Clin Res 1969;1:94-108.
- Massa RN, Minutello K, Mesfin FB. Neuroanatomy, cavernous sinus. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2020.
- Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997;25:1228-35.
- Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 2019;60:693-9.
- French DM, Bridges EP, Hoskins MC, Andrews CM, Nelson CH. Myasthenic crisis in pregnancy. Clin Pract Cases Emerg Med 2017;1:291-4.
- Cardone A, Congedo E, Aceto P, Sicuranza R, Chine E, Caliandro F, et al. Perioperative evaluation of myasthenia gravis. Ann Ital Chir 2007;78:359-65.
- Jordan A, Freimer M. Recent advances in understanding and managing myasthenia gravis. F1000Res 2018;7:F1000 Faculty Rev-1727.
- Mao Z, Hu X, Lu Z, Hackett ML. Prognostic factors of remission in myasthenia gravis after thymectomy. Eur J Cardiothorac Surg 2015;48:18-24.
- O’Connor JC, McCusker RH, Strle K, Johnson RW, Dantzer R, Kelley KW. Regulation of IGF-I function by proinflammatory cytokines: At the interface of immunology and endocrinology. Cell Immunol 2008;252:91-110.
- Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev 2005;205:72-93.
- Redelman D, Welniak LA, Taub D, Murphy WJ. Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network. Cell Immunol 2008;252:111-21.
- Le Panse R, Bismuth J, Cizeron-Clairac G, Weiss JM, Cufi P, Dartevelle P, et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 2010;43:401-12.